Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
Journal
The lancet. HIV
Journal Volume
10
Journal Issue
8
Date Issued
2023-08
Author(s)
Ogbuagu, Onyema
Segal-Maurer, Sorana
Ratanasuwan, Winai
Avihingsanon, Anchalee
Brinson, Cynthia
Workowski, Kimberly
Antinori, Andrea
Yazdanpanah, Yazdan
Trottier, Benoit
Wang, Hui
Margot, Nicolas
Dvory-Sobol, Hadas
Rhee, Martin S
Baeten, Jared M
Molina, Jean-Michel
GS-US-200-4625 investigators
Abstract
Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is in development as a long-acting agent for treating and preventing HIV-1. We aimed to evaluate the efficacy and safety of lenacapavir with an optimised background regimen in adults living with multidrug-resistant HIV-1 up to 52 weeks.
SDGs
Type
journal article